QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dmd.105.008904v1 34/7/1198    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by He, P. Articles by von Moltke, L. L. Search for Related Content PubMed PubMed Citation Articles by He, P. Articles by von Moltke, L. L.

FACTORS INFLUENCING MIDAZOLAM HYDROXYLATION ACTIVITY IN HUMAN LIVER MICROSOMES

Clinical/Translational Pharmacology Program (P.H., D.J.G., L.L.v.M.) and Comparative and Molecular Pharmacogenetics Laboratory (M.H.C.), Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine and Tufts-New England Medical Center, Boston, Massachusetts

The cytochrome P450 3A (CYP3A) subfamily (mainly CYP3A4 and CYP3A5) is responsible for metabolizing approximately half of currently marketed drugs, but with considerable interindividual variability in expression and function. To investigate factors contributing to this variability, rates of midazolam (MDZ) 1'-hydroxylation and CYP3A4 and CYP3A5 protein content were determined using a set of 54 human liver microsomes (HLMs). Genetic factors investigated included CYP3A4 and CYP3A5 single nucleotide polymorphisms (SNPs) and haplotypes, CYP3A4 mRNA alternative splicing, and CYP3A4 transcriptional start and polyadenylation sites. Demographic and environmental factors investigated included age, gender, and histories of smoking and alcohol consumption. MDZ 1'-hydroxylation rates varied from 0.025 to 3.106 nmol/min/mg protein, with significant correlation to CYP3A4 protein content (r_s = 0.92, P < 0.001) but less robust correlation to CYP3A5 protein content (r_s = 0.60, P < 0.001). We identified eight CYP3A4 SNPs (five novel) and nine CYP3A5 SNPs (one novel), as well as seven CYP3A4 and two CYP3A5 haplotypes (all novel). No influence of genotype or haplotype on MDZ 1'-hydroxylation rate was observed, although CYP3A5*3A (g.6986a>g; g.31611c>t) carriers had lower CYP3A5 protein content compared with noncarriers (P = 0.004). No alternative splicing of CYP3A4 mRNA was found. Likewise, only a single transcriptional start site and polyadenylation site for CYP3A4 mRNA were identified. Subjects with a history of alcohol consumption had 2.2-fold higher median MDZ 1'-hydroxylation (P = 0.017), whereas no influence of age, gender, or smoking was evident. In conclusion, the investigated genetic factors did not contribute substantially to the large interindividual variability in midazolam hydroxylation, although alcohol consumption has a discernable but modest influence.

This article has been cited by other articles:

				L. Gan, L. L. von Moltke, L. A. Trepanier, J. S. Harmatz, D. J. Greenblatt, and M. H. Court Role of NADPH-Cytochrome P450 Reductase and Cytochrome-b5/NADH-b5 Reductase in Variability of CYP3A Activity in Human Liver Microsomes Drug Metab. Dispos., January 1, 2009; 37(1): 90 - 96. [Abstract] [Full Text] [PDF]

				D. J. Greenblatt and L. L. von Moltke Gender Has a Small but Statistically Significant Effect on Clearance of CYP3A Substrate Drugs J. Clin. Pharmacol., November 1, 2008; 48(11): 1350 - 1355. [Abstract] [Full Text] [PDF]

				M. A. Felmlee, H.-K. Lon, F. J. Gonzalez, and A.-M. Yu Cytochrome P450 Expression and Regulation in CYP3A4/CYP2D6 Double Transgenic Humanized Mice Drug Metab. Dispos., February 1, 2008; 36(2): 435 - 441. [Abstract] [Full Text] [PDF]

				J. M. van der Bol, R. H.J. Mathijssen, W. J. Loos, L. E. Friberg, R. H.N. van Schaik, M. J.A. de Jonge, A. S.Th. Planting, J. Verweij, A. Sparreboom, and F. A. de Jong Cigarette Smoking and Irinotecan Treatment: Pharmacokinetic Interaction and Effects on Neutropenia J. Clin. Oncol., July 1, 2007; 25(19): 2719 - 2726. [Abstract] [Full Text] [PDF]

				J. B. Dennison, D. R. Jones, J. L. Renbarger, and S. D. Hall Effect of CYP3A5 Expression on Vincristine Metabolism with Human Liver Microsomes J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 553 - 563. [Abstract] [Full Text] [PDF]

				P. He, M. H. Court, D. J. Greenblatt, and L. L. von Moltke Human Pregnane X Receptor: Genetic Polymorphisms, Alternative mRNA Splice Variants, and Cytochrome P450 3A Metabolic Activity. J. Clin. Pharmacol., November 1, 2006; 46(11): 1356 - 1369. [Abstract] [Full Text] [PDF]